Table 3. Base case results.
| Outcomes | Pembrolizumab plus EP | Placebo plus EP | Difference |
|---|---|---|---|
| LYs | 1.43 | 1.13 | 0.30 |
| PFS state | 0.57 | 0.45 | 0.12 |
| PS state | 0.86 | 0.68 | 0.18 |
| QALYs | 1.01 | 0.79 | 0.22 |
| PFS state | 0.46 | 0.35 | 0.11 |
| PS state | 0.55 | 0.44 | 0.11 |
| Costs, $US | 126,362 | 44,890 | 81,472 |
| 1st-line drug acquisition costs | 94,384 | 3,600 | 90,784 |
| 2nd-line drug acquisition costs | 1,439 | 614 | 825 |
| Drug administration cost | 8,680 | 8,111 | 569 |
| AEs management (first-line) | 1,250 | 978 | 272 |
| AEs management(second-line) | 13,572 | 23,180 | -9,608 |
| Follow-up visit | 3,482 | 4,612 | -1,130 |
| Supportive care | 817 | 607 | 210 |
| Death cost | 2,738 | 3,188 | -451 |
| ICER, $US | |||
| Per LY | 271,574 | ||
| Per QALY | 334,373 |
EP: etoposide-platinum; LY: life-year; QALY: quality-adjusted life-year; PFS: progression-free survival; PS: progressed survival; ICER: incremental cost-effectiveness ratio.